Novel Live-Attenuated Rabies Vaccine

The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge.

Potential Commercial Applications: Competitive Advantages:
  • Rabies vaccine design and development
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Rabies virus research
  • Live attenuated vaccine shows greater efficacy than older inactivated vaccine
  • 100% animal survival conferred by a single inoculation before lethal challenge

Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)

Related Invention(s):


Xianfu Wu (CDC)  ➽ more inventions...

Charles Rupprecht (CDC)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 7,863,041 issued 2011-01-04
U.S. Pat: 8,865,461 issued 2014-10-21
US Application No. 12/090,083
US Application No. 12/956,949

Wu X, et al. PMID 21514343
Wu X, et al. PMID 17681631
Bankovskiy D, et al. PMID 18634508
Wu X, Rupprecht CE. PMID 17850911
Franka R, et al. PMID 21514343

Licensing Contact:
Jeremiah Mitzelfelt,
Phone: 301-443-8518

OTT Reference No: E-326-2013-0
Updated: Nov 15, 2013